Lung Cancer News

A novel liquid biopsy test can help determine whether patients with oligometastatic non-small cell lung cancer will benefit more from targeted, high-dose radiation instead of drug-based therapy, according to study results.

An FDA advisory committee voted 10-2 that the results of a confirmatory trial for the targeted lung cancer drug sotorasib cannot be interpreted reliably.

In this episode, host Shikha Jain, MD, speaks with Douglas Micalizzi, MD, and Lecia Sequist, MD, about adopting novel technologies for early detection, public perception of prevention screening and more.

Takeda will work with the FDA toward voluntary withdrawal of its lung cancer therapy mobocertinib from the U.S. market, according to a company press release.

ASCO released a research statement outlining new recommendations regarding the appropriate assessment of ovarian toxicity in cancer clinical trials.

High-dose hyperfractionated thoracic radiotherapy with concurrent chemotherapy improved outcomes for patients with limited-stage small cell lung cancer, according to randomized phase 3 study results presented at ASTRO Annual Meeting.

The FDA announced several regulatory actions.

Amivantamab plus lazertinib improved PFS compared with osimertinib as first-line therapy in adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer, according to the agent’s manufacturer.

Nearly seven in 10 premature cancer-related deaths among women could have been avoided through primary prevention, early detection or suitable access to cancer care, according to a report.

New diagnoses for six of the most common cancer types sharply declined in the U.S. in early 2020 — along with the volume of pathology reports — largely due to the start of the COVID-19 pandemic, according to data released by NCI.